DJ-1 Plays an Important Role in Homoharringtonine-Induced Apoptosis of Imatinib-Resistant Chronic Myeloid Leukemia Cells

被引：0
|
作者：
Zhou, Xuan [1 ]
Xu, Na [1 ]
Li, Rong [2 ]
Li, Lin [1 ]
Ding, Li [1 ]
Lu, Qisi [1 ]
Li, Yulin [3 ]
Liu Xiaoli [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[2] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China
[3] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Guangdong, Peoples R China
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells
    A Puissant
    M Dufies
    S Raynaud
    J-P Cassuto
    P Auberger
    Leukemia, 2010, 24 : 1099 - 1101
  • [32] Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
    Giles, F. J.
    Kantarjian, H. M.
    le Coutre, P. D.
    Baccarani, M.
    Mahon, F-X
    Blakesley, R. E.
    Gallagher, N. J.
    Gillis, K.
    Goldberg, S. L.
    Larson, R. A.
    Hochhaus, A.
    Ottmann, O. G.
    LEUKEMIA, 2012, 26 (05) : 959 - 962
  • [33] QUALITY OF LIFE AND SYMPTOM PROFILE IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA
    Ionova, I.
    Nikitina, T.
    Gritsenko, T.
    Ivanova, V.
    Kuchma, G.
    Fedorenko, D.
    Kurbatova, K.
    HAEMATOLOGICA, 2012, 97 : 314 - 314
  • [34] Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
    F J Giles
    H M Kantarjian
    P D le Coutre
    M Baccarani
    F-X Mahon
    R E Blakesley
    N J Gallagher
    K Gillis
    S L Goldberg
    R A Larson
    A Hochhaus
    O G Ottmann
    Leukemia, 2012, 26 : 959 - 962
  • [35] Targeted therapy for the treatment of imatinib-resistant chronic myeloid leukemia: A pharmacogenetic analysis.
    Shah, N
    Nicoll, J
    Sawyers, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P17 - P17
  • [36] Inflammation plays an important role in the progression of chronic myeloid leukemia
    Langhammer, Melanie
    Schopf, Julia
    Jaquet, Timo
    Horn, Katharina
    Angel, Moritz
    Mohl, Daniel
    Lagies, Simon
    Spohr, Corinna
    Christen, Daniel
    Uhl, Franziska Maria
    Maie, Tiago
    Jacobi, Henrike
    Feyerabend, Thorsten B.
    Huber, Julia
    Panning, Marcus
    Sitaru, Cassian
    Costa, Ivan
    Zeiser, Robert
    Aumann, Konrad
    Becker, Heiko
    Braunschweig, Till
    Koschmieder, Steffen
    Kammerer, Bernd
    Shoumariyeh, Khalid
    Huber, Michael
    Schemionek-Reinders, Mirle
    Brummer, Tilman
    Halbach, Sebastian
    CANCER RESEARCH, 2024, 84 (06)
  • [37] Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation
    Yusuf Baran
    Jacek Bielawski
    Ufuk Gunduz
    Besim Ogretmen
    Journal of Cancer Research and Clinical Oncology, 2011, 137 : 1535 - 1544
  • [38] Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation
    Baran, Yusuf
    Bielawski, Jacek
    Gunduz, Ufuk
    Ogretmen, Besim
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (10) : 1535 - 1544
  • [39] AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells
    M Nieborowska-Skorska
    S Flis
    T Skorski
    Leukemia, 2014, 28 : 2416 - 2418
  • [40] Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR ABL mutation-independent imatinib resistance
    Lee, Wongeun
    Lee, Cho-Rong
    Kang, Jung-Ah
    Yang, Taewoo
    Park, Sung-Gyoo
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
12345